Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGT | P01019 | 2/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036241 | 0.94 | AGT (0.51) | AGTAGTR1AGTR2 | |
| SCHEMBL6023846 | 0.92 | AGTR1 (0.51) | AGTAGTR1AGTR2 | |
| SCHEMBL5033674 | 0.92 | AGT (0.54) | AGTAGTR1AGTR2 | |
| SCHEMBL6023244 | 0.87 | AGTR1 (0.54) | AGTAGTR1AGTR2 | |
| SCHEMBL5037889 | 0.86 | AGT (0.55) | AGTAGTR1AGTR2 | |
| SCHEMBL5033808 | 0.86 | AGT (0.50) | AGTAGTR1AGTR2 | |
| SCHEMBL5043092 | 0.85 | AGT (0.49) | AGTAGTR1AGTR2 | |
| SCHEMBL5037962 | 0.85 | AGT (0.49) | AGTAGTR1AGTR2 | |
| SCHEMBL30555819 | 0.84 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL5036249 | 0.83 | AGT (0.53) | AGTAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653950-B1 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | NICOX S.A. (FR) | 2006-12-07 | — | — | US | disclosed |
| EP-1653950-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011646-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | AGTR2, AGTR1, REN | AGT 4/4885AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.